Home › FDA approves Genentech drug for advanced lung cancer
 

Keywords :   


FDA approves Genentech drug for advanced lung cancer

2015-12-11 23:03:49| Biotech - Topix.net

The Food and Drug Administration on Friday conditionally approved an experimental Genentech drug for patients with a certain type of lung cancer who have few other options. Alecensa won accelerated approval for patients with advanced non-small cell lung cancer with a mutation in a gene called ALK who have relapsed after treatment with Pfizer Inc.'s Xalkori or who could not tolerate that drug.

Tags: advanced drug cancer lung

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
17.05Bank of England plans expansion of Leeds base
17.05Henkel Laundry Patent Details Transfer of Encapsulated Fragrance with Dryer Balls
17.05The Recycling Partnership Welcomes McDonalds Corporation to the Polypropylene Recycling Coalition and Awards its 100th Recycling Facility Grant
17.05Cooking temperatures sufficient to kill H5N1 in meat
17.05This Week in Waste: Top Stories May 13 May 16, 2024
17.05New Pizza Box Recycling Bins Rolling Out in Central Park, Aiming to Limit Rodent Issues
17.05WM Celebrates Completion of $23 Million in Upgrades at Pittsburgh Facility
17.05Bioenergy Devco's Maryland Bioenergy Center Recycles Food Waste at Full Nameplate Capacity
More »